Table 1. Patient characteristics by... | American Society of Hematology

Table 1.

Patient characteristics by fusion status

		Kinase-activating fusion				P
		No		Yes
	N	N	%	N	%
Number screened	105	89	85	16	15
Age at diagnosis						.003
<10 y	49	47	96	2	4
≥10 y	56	42	75	14	25
Median (range)	10.6 (1.3-18.0)	7.4 (1.3-17.1)		13.5 (1.8-18.0)		.016
Leukocyte count at diagnosis, ×10⁹/L						.38
<50	34	27	79	7	21
≥50	71	62	87	9	13
Median (range)	70.0 (1.3-726.3)	75.2 (1.3-726.3)		51.8 (5.5-363.8)		.43
Sex						.031
Female	46	43	93	3	7
Male	59	46	87	13	22
Ethnicity*						.014
Hispanic or Latino	24	17	71	7	29
Non-Hispanic	74	68	92	6	8
Ethnicity not known	7	4	57	3	43
IKZF1 deleted*†						<.001
No	66	61	92	5	8
Yes	28	17	61	11	39
Cytogenetics
Hyperdiploidy (51-65 chromosomes)	14	14	100	0	0	.12
ETV6-RUNX1	16	16	100	0	0	.12
KMT2A rearrangement	8	7	88	1	13	1.00
TCF3-PBX1	8	7	88	1	13	1.00
Achieve CR	96	82	85	14	15	.62
MRD*						.08
High	10	8	80	2	20
Low	72	64	89	8	11
Indeterminate	14	10	71	4	28
Final risk						.45
High	81	70	86	14	17
Very high	15	12	80	3	20

		Kinase-activating fusion				P
		No		Yes
	N	N	%	N	%
Number screened	105	89	85	16	15
Age at diagnosis						.003
<10 y	49	47	96	2	4
≥10 y	56	42	75	14	25
Median (range)	10.6 (1.3-18.0)	7.4 (1.3-17.1)		13.5 (1.8-18.0)		.016
Leukocyte count at diagnosis, ×10⁹/L						.38
<50	34	27	79	7	21
≥50	71	62	87	9	13
Median (range)	70.0 (1.3-726.3)	75.2 (1.3-726.3)		51.8 (5.5-363.8)		.43
Sex						.031
Female	46	43	93	3	7
Male	59	46	87	13	22
Ethnicity*						.014
Hispanic or Latino	24	17	71	7	29
Non-Hispanic	74	68	92	6	8
Ethnicity not known	7	4	57	3	43
IKZF1 deleted*†						<.001
No	66	61	92	5	8
Yes	28	17	61	11	39
Cytogenetics
Hyperdiploidy (51-65 chromosomes)	14	14	100	0	0	.12
ETV6-RUNX1	16	16	100	0	0	.12
KMT2A rearrangement	8	7	88	1	13	1.00
TCF3-PBX1	8	7	88	1	13	1.00
Achieve CR	96	82	85	14	15	.62
MRD*						.08
High	10	8	80	2	20
Low	72	64	89	8	11
Indeterminate	14	10	71	4	28
Final risk						.45
High	81	70	86	14	17
Very high	15	12	80	3	20

CR, complete remission.

The P value excludes unknowns.

Ninety-four of the 105 were also screened for IKZF1.